ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 396

Clinical Manifestations and Comparison of Subtypes of Juvenile Idiopathic Inflamatory Myopathies: Data from the REMICAM Registry

Jesús Loarce-Martos1, Carmen Larena 2, M. Ángeles Blázquez 1, Beatriz Joven-Ibáñez 3, Patricia Carreira 3, Julia Martinez Barrio 4, Francisco javier López-Longo 5, Juan Carlos Lopez-Robledillo 6, Raquel Almodovar-Gonzalez 7, Irene Llorente 8, Eva Tomero-Muriel 8, Paloma García-De La Peña 9, Henry Moruno 10, Ana Pérez-Gómez 11, Tatiana Cobo-Ibáñez 12, María Jesús García De Yébenes 13 and Laura Nuño 14, 1Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Hospital Universitario Gregorio Marañón, Madrid, Spain, 5Hospital Universitario Gregorio Marañón, Madrid, 6Hospital Niño Jesús, Madrid, Spain, 7Hospital Universitario Fundación Alcorcón, Madrid, Spain, 8Hospital Universitario La Princesa, Madrid, Spain, 9Hospital HM San Chinarro, Madrid, Spain, 10Hospital Universitario Príncipe de Asturias, Madrid, 11Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, 12Hospital Universitario Infanta Sofía, Madrid, 13Instituto de Salud Musculoesquelética - Inmusc., Madrid, Spain, 14Hospital Universitario La Paz, Madrid

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Idiopathic Inflammatory Myopathies (IIM) and juvenile dermatomyositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Muscle Biology, Myositis & Myopathies Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are a heterogeneous group of autoimmune diseases affecting children, characterized by symmetric muscular weakness, cutaneous rash and systemic organ involvement. The clinical manifestations of the IIMs differ between children and adults, for example, JIIM have a higher prevalence of calcinosis, lipodystrophy and vasculopathy, as well as a minor incidence of neoplastic disease or interstitial pneumonia. Given the low incidence of the JIIM, there are few studies describing the characteristics of this disease and its different subtypes.

The objective of this study is to describe the demographic, clinical and analytical characteristics of patients with JIIM from the multicentric REMICAM registry, and to compare those measures between polymyositis (PM) and juvenile dermatomyositis (JDM) subgroups.

Methods: A multicenter retrospective study from the REMICAM registry was performed. Patients were selected if they were 18 years or younger at onset of JIIM and met definite or probable criteria for IIM as defined by the modified Bohan and Peter criteria. We included patients with JDM or PM subgroups, overlap myositis patients were excluded.

Results: A total of 86 patients were included, 12 (14%) classified as PM and 74 (86%) as JDM. 70% were women, most of the subjects were Caucasian (96%). Disease characteristics are shown in Table 1. 13% of the patients had fever and 15% weight loss. Regarding musculoskeletal manifestations, 44% and 28% had arthralgias and arthritis, respectively, and 93% presented muscular weakness. Gottron sign was present in 76% of the patients, and calcinosis was present in 31.4%.  CPK and aldolase levels at diagnosis are 431 U/L and 8 U/L respectively. Antinuclear antibody (ANA) was positive in 40% of the sample, but only 2 cases were anti-Jo1 positive. The rest of the complementary analysis are shown in table 2.

Conclusion: JDM was the most frequent clinical form of JIIM in our study, which corresponded to more than 80% of the cases, like other cohorts. The most frequent manifestations in patients with JIIM of our registry were the muscular and dermatological ones, but an important group also presented arthralgia/arthritis and fever. There was no statistical difference between both groups, regardless, cutaneous manifestations, myalgias and dysphagia were more common in JDM group, as well as higher CPK values and aldolase. PM group patients were older at diagnosis, had more fever and arthritis, also, cytopenia and ANA positivity were more frequent in this subtype.


Table 1


Table 2


Disclosure: J. Loarce-Martos, None; C. Larena, None; M. Blázquez, None; B. Joven-Ibáñez, Celgene, 8, Novartis, 8, MSD, 8, Pfizer, 8, AbbVie, 8, Janssen, 8; P. Carreira, None; J. Martinez Barrio, None; F. López-Longo, None; J. Lopez-Robledillo, None; R. Almodovar-Gonzalez, None; I. Llorente, None; E. Tomero-Muriel, None; P. García-De La Peña, None; H. Moruno, None; A. Pérez-Gómez, None; T. Cobo-Ibáñez, None; M. García De Yébenes, None; L. Nuño, None.

To cite this abstract in AMA style:

Loarce-Martos J, Larena C, Blázquez M, Joven-Ibáñez B, Carreira P, Martinez Barrio J, López-Longo F, Lopez-Robledillo J, Almodovar-Gonzalez R, Llorente I, Tomero-Muriel E, García-De La Peña P, Moruno H, Pérez-Gómez A, Cobo-Ibáñez T, García De Yébenes M, Nuño L. Clinical Manifestations and Comparison of Subtypes of Juvenile Idiopathic Inflamatory Myopathies: Data from the REMICAM Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/clinical-manifestations-and-comparison-of-subtypes-of-juvenile-idiopathic-inflamatory-myopathies-data-from-the-remicam-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-manifestations-and-comparison-of-subtypes-of-juvenile-idiopathic-inflamatory-myopathies-data-from-the-remicam-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology